MedTrace Logo

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer

NCT03111901 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2019-07-12

No results posted yet for this study

Summary

This study will evaluate the safety and disease control rate of the combination of pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or renal cell cancer.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab solution

DRUG

Interleukin-2

Interleukin-2 solution

Sponsors & Collaborators

  • William Grosh, MD

    lead OTHER

Principal Investigators

  • William W Grosh, MD · University of Virginia Health System

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-29
Primary Completion
2023-10-31
Completion
2023-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03111901 on ClinicalTrials.gov